[go: up one dir, main page]

MX2010008638A - Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas. - Google Patents

Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas.

Info

Publication number
MX2010008638A
MX2010008638A MX2010008638A MX2010008638A MX2010008638A MX 2010008638 A MX2010008638 A MX 2010008638A MX 2010008638 A MX2010008638 A MX 2010008638A MX 2010008638 A MX2010008638 A MX 2010008638A MX 2010008638 A MX2010008638 A MX 2010008638A
Authority
MX
Mexico
Prior art keywords
furo
thieno
pyridines
pyridine
including conditions
Prior art date
Application number
MX2010008638A
Other languages
English (en)
Inventor
Xin Chen
Arno G Steinig
Qinghua Weng
Hanqing Dong
Meizhong Jin
Mark J Mulvihill
Jing Wang
Ti Wang
An-Hu Li
Andrew Kleinberg
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of MX2010008638A publication Critical patent/MX2010008638A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de furo[3,2-c]piridina y tieno[3,2-c]piridina de la fórmula (I), y sales farmacéuticamente aceptables de los mismos, preparación, intermediarios, composiciones farmacéuticas y uso, tal como en tratamiento de enfermedad, incluyendo cánceres, incluyendo condiciones en las cuales EMT está implicado, incluyendo condiciones mediadas por actividad de proteína cinasa tal como RON y/o MET.
MX2010008638A 2008-02-06 2009-02-06 Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas. MX2010008638A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6380008P 2008-02-06 2008-02-06
US11955308P 2008-12-03 2008-12-03
PCT/US2009/033311 WO2009100282A1 (en) 2008-02-06 2009-02-06 Furo-and thieno[3,2-c] pyridines

Publications (1)

Publication Number Publication Date
MX2010008638A true MX2010008638A (es) 2010-08-30

Family

ID=40524808

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008638A MX2010008638A (es) 2008-02-06 2009-02-06 Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas.

Country Status (19)

Country Link
US (1) US8022206B2 (es)
EP (1) EP2265616B8 (es)
JP (1) JP2011511094A (es)
KR (1) KR20110014971A (es)
CN (1) CN102007127A (es)
AR (1) AR070317A1 (es)
AU (1) AU2009212338A1 (es)
BR (1) BRPI0908050A2 (es)
CA (1) CA2711078A1 (es)
CL (1) CL2009000275A1 (es)
EA (1) EA201070929A1 (es)
ES (1) ES2451024T3 (es)
IL (1) IL206758A0 (es)
MX (1) MX2010008638A (es)
PE (1) PE20091414A1 (es)
TW (1) TW200944201A (es)
UY (1) UY31638A1 (es)
WO (1) WO2009100282A1 (es)
ZA (1) ZA201005554B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011100502A1 (en) * 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
WO2011109593A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Substituted-5-aminopyrrolo/pyrazolopyridines
JP2013525476A (ja) * 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
US10614666B2 (en) 2011-04-20 2020-04-07 Video Gaming Technologies, Inc. Gaming machines with free play bonus mode presenting only winning outcomes
JP6118808B2 (ja) * 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物
AU2013235487B2 (en) * 2012-03-23 2017-09-07 Memorial Sloan-Kettering Cancer Center Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
MX355943B (es) 2013-06-26 2018-05-07 Abbvie Inc Carboxamidas primarias como inhibidores de btk.
US9907791B2 (en) * 2014-03-14 2018-03-06 University Of Utah Research Foundation Ron inhibitors for use in preventing and treating bone loss
CN103923081B (zh) * 2014-04-14 2017-06-27 武汉光谷人福生物医药有限公司 化合物及其制备方法和应用
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN106866447A (zh) * 2017-03-30 2017-06-20 成都绿林科技有限公司 一种合成对乙酰基苯甲酰胺的方法
US10957159B2 (en) 2018-04-12 2021-03-23 Aristocrat Technologies Australia Pty Limited Gaming machine and method for displaying a free spin count-up
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
AU2023357583A1 (en) 2022-10-03 2025-04-17 Daiichi Sankyo Company, Limited Imidazopyridine derivatives with bicyclic structure
JP2026500029A (ja) * 2022-12-15 2026-01-05 睿健毅聯医薬科技（成都）有限公司 間葉系細胞から上皮細胞への形質転換及びリプログラミングを誘導する誘導剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100875380B1 (ko) * 2001-06-23 2008-12-23 아벤티스 파마슈티칼스 인크. 단백질 키나제 억제제로서의 피롤로피리미딘
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
ES2305435T3 (es) * 2002-01-10 2008-11-01 Bayer Healthcare Ag Inhibidores de la rho-quinasa.
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
WO2004069160A2 (en) 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
US7230098B2 (en) * 2003-02-26 2007-06-12 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US7592352B2 (en) * 2003-05-06 2009-09-22 Smithkline Beecham Corporation Substituted thieno and furo-pyridines
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
EP1786777A1 (en) * 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
CA2578066C (en) * 2004-08-26 2011-10-11 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
ATE492544T1 (de) * 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
CA2601983A1 (en) * 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
BRPI0520482A2 (pt) * 2005-08-16 2009-05-12 Hoffmann La Roche amidas do ácido 4-amino-tieno [3,2-c] piridina-7-carboxìlico
BRPI0615781A2 (pt) * 2005-09-01 2009-06-16 Array Biopharma Inc compostos inibidores de raf e métodos de uso destes
JP2009514899A (ja) * 2005-11-04 2009-04-09 スミスクライン ビーチャム コーポレーション チエノピリジンＢ−Ｒａｆキナーゼ阻害剤
KR101146852B1 (ko) * 2005-12-05 2012-05-16 화이자 프로덕츠 인크. Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
DE602007004092D1 (de) 2006-03-22 2010-02-11 Vertex Pharma C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
AU2007240568A1 (en) 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
BRPI0720695A2 (pt) * 2006-12-21 2014-02-18 Plexxikon Inc Compostos e métodos para modulação de cinase, e indicações para estes
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
CL2008001540A1 (es) * 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
WO2009053737A2 (en) * 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
AR069393A1 (es) 2007-11-21 2010-01-20 Imclone Systems Inc Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
EP2288383A1 (en) 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
KR101034351B1 (ko) 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물

Also Published As

Publication number Publication date
KR20110014971A (ko) 2011-02-14
AU2009212338A1 (en) 2009-08-13
ZA201005554B (en) 2011-04-28
EP2265616A1 (en) 2010-12-29
JP2011511094A (ja) 2011-04-07
TW200944201A (en) 2009-11-01
EP2265616B1 (en) 2013-11-20
UY31638A1 (es) 2009-09-30
PE20091414A1 (es) 2009-09-23
US20090197864A1 (en) 2009-08-06
CN102007127A (zh) 2011-04-06
BRPI0908050A2 (pt) 2015-08-11
CA2711078A1 (en) 2009-08-13
AR070317A1 (es) 2010-03-31
ES2451024T3 (es) 2014-03-26
EP2265616B8 (en) 2014-01-08
EA201070929A1 (ru) 2011-04-29
IL206758A0 (en) 2010-12-30
CL2009000275A1 (es) 2009-06-12
US8022206B2 (en) 2011-09-20
WO2009100282A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
MX2010008638A (es) Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas.
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
JO2787B1 (en) Alternative amide derivatives and methods of use
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
MX2012013082A (es) Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
WO2008079291A3 (en) Substituted heterocycles and methods of use
AU2009253235A8 (en) Polysubstituted derivatives of 2-heteroaryl-6-phenyl-imidazo[1,2- a] pyridines, and preparation and therapeutic use thereof
UA92637C2 (en) Pyridine[3,4-b]pyrazinones
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
TN2018000078A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
MX2009008486A (es) Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor.
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
PH12012501800A1 (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
PT2432760E (pt) Derivados de espiro [2,4] heptano ligados em ponte como agonistas do receptor fprl2 e/ou receptor alx
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
EP1973407A4 (en) SPIRO COMPOUNDS AND METHODS OF USE
MX350418B (es) Inhibidores de bifluorodioxalano-amino-bencimidazol quinasa para el tratamiento de cáncer, inflamación autoinmune y trastornos del sistema nervioso central.
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.

Legal Events

Date Code Title Description
FG Grant or registration